In a deal consistent with the Swiss pharma giant’s focused prioritized therapy strategy, Novartis (NOVN: VX) today said it has signed an agreement to divest ‘front of eye’ ophthalmology assets to Canada-based Bausch + Lomb (TSK: BLCO).
The transaction is valued up to 2.5 billion, including $1.75 billion in upfront cash, plus additional milestone payments.
The deal includes Xiidra (lifitegrast ophthalmic solution), the first approved prescription treatment for the signs and symptoms of dry eye disease. Novartis acquired the product from Japan’s Takeda (TYO: 4502) in a transaction that included a $3.4 billion upfront payment with potential milestone payments of up to $1.9 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze